ImmunoPrecise Antibodies Ltd. (IPA)
Company Description
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally.
It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.
In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.
The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel.
Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes.
Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain.
It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts.
The company was incorporated in 1983 and is headquartered in Victoria, Canada.
| Country | Canada |
| Founded | 1983 |
| IPO Date | Jan 3, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Dr. Jennifer Lynne Bath Ph.D. |
Contact Details
Address: 880 - 580 Hornby Street Vancouver, A1 V6C3B6 British Columbia, Canada | |
| Phone | 6048060626 |
| Website | ipatherapeutics.com |
Stock Details
| Ticker Symbol | IPA |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001715925 |
| CUSIP Number | 45257F200 |
| ISIN Number | CA45257F2008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | Chief Executive Officer, President and Non-Independent Director |
| Brad McConn | Chief Financial Officer |
| Dr. Ilse Roodink | Chief Scientific Officer |
| David E. Orton | Chief Operating Officer |
| Carla Dahl | Vice President of Marketing |
| Dr. Barry Neil Duplantis | Vice President of Client Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2023 | 6-K | Report of foreign issuer |
| Nov 16, 2023 | 6-K | Report of foreign issuer |
| Nov 13, 2023 | 6-K | Report of foreign issuer |
| Oct 25, 2023 | 6-K | Report of foreign issuer |
| Oct 23, 2023 | 6-K | Report of foreign issuer |
| Oct 20, 2023 | 6-K | Report of foreign issuer |
| Sep 26, 2023 | 6-K | Report of foreign issuer |
| Sep 25, 2023 | 6-K | Report of foreign issuer |
| Sep 19, 2023 | 6-K | Report of foreign issuer |
| Sep 18, 2023 | 6-K | Report of foreign issuer |